Administration of cisplatin in three patients with carboplatin hypersensitivity: Is skin testing useful?

Anti-Cancer Drugs

Volumn 21, Issue 3, 2010, Pages 333-338

  Syrigou, Ekaterini ^a   Makrilia, Nektaria ^a   Vassias, Antonios ^a   Nikolaidis, Ilias ^a   Xyla, Vassilia ^a   Manolopoulos, Leonidas ^a   Syrigos, Kostas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Carboplatin; Cisplatin; Hypersensitivity reactions; Skin tests

Indexed keywords

ADRENALIN; AMLODIPINE; ANTIHISTAMINIC AGENT; CANDESARTAN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; METFORMIN; PACLITAXEL; PEMETREXED; SALBUTAMOL; SODIUM CHLORIDE; TOPOTECAN; VALSARTAN;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL SWELLING; ADULT; AGED; ARTICLE; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER SURGERY; CARBOPLATIN HYPERSENSITIVITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CROSS REACTION; DESENSITIZATION; DIABETES MELLITUS; DIAPHORESIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DYSPNEA; ERYTHEMA; FEMALE; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; LUNG NON SMALL CELL CANCER; MALE; MESOTHELIOMA; OVARY CANCER; OVARY CARCINOMA; OXYGEN THERAPY; PREMEDICATION; PRICK TEST; PRIORITY JOURNAL; SIDE EFFECT; SKIN TEST; TACHYPNEA; URTICARIA;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN E; INTRADERMAL TESTS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; SKIN TESTS;

EID: 76649118099     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833418c0     Document Type: Article

References (49)

1. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24:253-262.
2. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19:3126-3129.
3. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981; 94:66-72.
4. Weidmann B, Mülleneisen N, Bojko P, Niederle N. Hypersensitivity reactions to carboplatin. Cancer 1994; 73:2218-2222.
5. Tonkin KS, Rubin P, Levin L. Carboplatin hypersensitivity: case reports and review of the literature. Eur J Cancer 1993; 29A:1356-1357.
6. Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989; 7:223-228.
7. Covens A, Carey M, Bryson P, Verma S, Fung KFM, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85:71-80.
8. Gore ME, Fryatt I,Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36:207-211. (Pubitemid 20061287)
9. Yu DY, Dahl GVH, Shames RS, Fisher PG. Weekly doses of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol 2001; 23:349-352.
10. Markman M, Kennedy A,Webster K, Peterson G, Kulp B, Belinson J. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite multiple prior platinum based regimens. Gynecol Oncol 1997; 65:434-436.
11. Morgan JS, Adams S, Mason MD. Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 1994; 30A:1205-1206.
12. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141-1145.
13. Hendrick AM, Simmons D, Cantwell BM. Allergic reactions to carboplatin. Ann Oncol 1992; 3:239-240.
14. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45-51.
15. Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M. Successful administration of carboplatin in patients with clinically documented hypersensitivity. Gynecol Oncol 2003; 89:429-433.
16. Kook H, Kim KM, Choi SH. Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization. Bone Marrow Transplant 1998; 21:727-729.
17. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15:13-18.
18. Moreno-Ancillo A, Domínguez-Noche C, Gil-Adrados AC, Cosmes PM, Duarte I, Mateos Y. Anaphylactoid reaction to carboplatin: successful desensitization. Allergol Immunopathol (Madr) 2003; 31:342-344.
19. Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001; 61:129-133.
20. Saif MW, Roy S, Ledbetter L, Madison J, Syrigos K. Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer oxaliplatin-induced hypersensitivity reaction. World J Gastroenterol 2007; 13:5277-5281.
21. Markman M, Zanotti K, Kulp B, Peterson G, Markman M. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 2003; 89:514-516.
22. Freedman SO, Krupey J. Respiratory allergy caused by platinum salts. J Allergy 1968; 42:233-237.
23. Morgan M, Bowers DC, Gruchalla RS, Khan DA. Safety and efficacy of repeated monthly carboplatin desensitization. J Allergy Clin Immunol 2004; 114:974-975.
24. Newman TAJ, Cullinan P, Lympany PA, Harris JM, Dowdeswell RJ, du Bois RM. Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med 1999; 160:435-438.
25. Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008; 8:56-62.
26. Cromwell O, Pepys J, Parish WE, Hughes EG. Specific IgE antibodies to platinum salts in sensitized workers. Clin Allergy 1979; 9:109-117.
27. Lee CW, Matulonis UA, Castells MC. Carboplain hypersensitivity: a 6-h 12- step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95:370-376.
28. Pichler WJ. Immune mechanism of drug hypersensitivity. Immunol Allergy Clin North Am 2004; 24:373-397.
29. Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41:2262-2267.
30. Robinson JB, Singh D, Bodurka-Bevers DC. Hypersensitivity reactions and the utility of oral and iv desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001; 82:550-558.
31. Dizon DS, Sabbatini PJ, Aghajanian C, Ensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84:378-382.
32. Zweizig S, Roman LD, Mudersprach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53:121-122.
33. Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, SaifMW, Syrigos KN. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 2009; 8:106-109.
34. National Cancer Institute, U.S. National Institute of Health. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http:// ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf (Publish date August 9, 2006; Accessed 30 August 2009).
35. Goldberg A, Confino-Cohen R, Fishman A, Beyth J, Altaras M. A modified prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996; 98:841-843.
36. Jones R, Ryan M, Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitization. Gynecol Oncol 2003; 89:112-115.
37. Lee C, Mauronis U, Castells M. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99:393-399.
38. Markman M, Hsieh F, Zanotti K,Webster K, Peterson G, Kulp B, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions. J Cancer Res Clin Oncol 2004; 130:25-28.
39. Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 2005; 104:640-643.
40. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574-580.
41. Markman M. Hypersensitivity reactions to carboplatin. [Letter to the editor]. Gynecol Oncol 2002; 84:353.
42. Markman M, Zanotti K, Peterson G, Kulp B,Webster K, Belinson J. Expanded experience with an inradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21:4611-4614.
43. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 2007; 197:199.e1-199.e5.
44. Gottlieb MJ, Nelson B, Perry W. Utility of skin test for allergy to carboplatin or cisplatin. J Allergy Clin Immunol 1998; 101:S139.
45. Porzio G, Marchetti P, Paris I, Narducci F, Ricevuto E, Ficorella C. Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. Eur J Gynaecol Oncol 2002; 23:335-336.
46. Kandel MJ, Loehr A, Harter P, Traut A, Gnauert K, du Bois A. Cisplatinum rechallenge in elapsed ovarian cancer patients with cisplatinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15:780-784.
47. Elligers KT, Davies M, Sanchis D, Ferencz T, Saif MW. Rechallenge with cisplatin in a patients with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? J Pancreas 2008; 9:197-202.
48. Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007; 119:726-730.
49. Warner E. Neurotoxicity of cisplatin and taxol. Gynecol Cancer 1995; 5:161-169.